Skip to main navigation Skip to search Skip to main content

Letter to the FDA Proposing Major Changes in the US Clozapine Package Insert Supported by Clozapine Experts Worldwide. Part II A Review of Fatal Outcomes in US Pharmacovigilance Data and Proposed Changes

  • Jose de Leon
  • , Ross J. Baldessarini
  • , Richard Balon
  • , John Bilbily
  • , Stanley N. Caroff
  • , Leslie Citrome
  • , Christoph U. Correll
  • , Robert O. Cotes
  • , John M. Davis
  • , Lynn E. DeLisi
  • , Justin Faden
  • , Oliver Freudenreich
  • , David R. Goldsmith
  • , Ronald Gurrera
  • , Richard C. Josiassen
  • , John M. Kane
  • , Deanna L. Kelly
  • , Matcheri S. Keshavan
  • , Robert S. Laitman
  • , Y. W.Francis Lam
    • Jonathan G. Leung, Raymond C. Love, Betsy McCollum, Ian R. McGrane, Jonathan M. Meyer, Henry A. Nasrallah, Frederick C. Nucifora, Anthony J. Rothschild, Jose M. Rubio, Martha Sajatovic, Deepak K. Sarpal, Georgios Schoretsanitis, Mujeeb Shad, Charles Shelton, Leo Sher, Balwinder Singh, Sandarsh Surya, Theodore R. Zarzar, Emilio J. Sanz, Carlos De las Cuevas

Research output: Contribution to journal › Review article › peer-review

32 Scopus citations

Fingerprint

Dive into the research topics of 'Letter to the FDA Proposing Major Changes in the US Clozapine Package Insert Supported by Clozapine Experts Worldwide. Part II A Review of Fatal Outcomes in US Pharmacovigilance Data and Proposed Changes'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science